[1]陆丹红,许 坚△.隔物灸联合阿瑞匹坦及昂丹司琼对晚期肺癌含顺铂方案化疗所致恶心呕吐的预防效果研究*[J].陕西中医,2020,(8):1084.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.018]
　LU Danhong,XU Jian..Effects of substance-partitioned moxibustion combined with aprepitant and ondansetron in preventing nausea and vomiting induced by chemotherapy with cisplatin for advanced lung cancer[J].,2020,(8):1084.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.018]
点击复制

隔物灸联合阿瑞匹坦及昂丹司琼对晚期肺癌含顺铂方案化疗所致恶心呕吐的预防效果研究*

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年8期
页码:
1084
栏目:
临床研究
出版日期:
2020-08-05

文章信息/Info

Title:
Effects of substance-partitioned moxibustion combined with aprepitant and ondansetron in preventing nausea and vomiting induced by chemotherapy with cisplatin for advanced lung cancer
作者:
陆丹红1; 许 坚2△
1.广州中医药大学第二临床医学院(广州 510405); 2.广州中医药大学第二附属医院(广州 510145)
Author(s):
LU Danhong; XU Jian.
The Second Clinical College of Guangzhou University of Traditional Chinese Medicine(Guangzhou 510405)
关键词:
隔物灸;  阿瑞匹坦;  昂丹司琼;  晚期肺癌;  顺铂;  恶心呕吐
Keywords:
Substance-partitioned moxibustion;  Aprepitant;  Ondansetron;  Advanced lung cancer;  Cisplatin;  Nausea and vomiting
分类号:
R734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2020.08.018
文献标志码:
A
摘要:
目的:探讨隔物灸联合阿瑞匹坦、昂丹司琼预防晚期肺癌患者顺铂化疗胃肠道毒副反应的临床效果。方法:对80例晚期肺癌化疗患者临床资料进行回顾性分析,单纯服用阿瑞匹坦及昂丹司琼者纳入对照组(n=46),在其基础上联合采取隔物灸治疗者纳入观察组(n=34)。比较化疗第1周期(T1)、化疗第2周期(T2)、化疗第3周期(T3)、化疗第4周期(T4)结束时,两组患者中医症状积分(嗳气反酸、饮食减少、疲乏无力)变化,分析化疗4周期内,两组患者恶心呕吐及非化疗药物不良反应发生情况。结果:T1结束时,两组各项中医症状积分比较,差异无统计学意义(P>0.05)。T2、T3、T4结束时,观察组嗳气反酸、饮食减少、疲乏无力中医症状积分与T1结束时比较,差异无统计学意义(P>0.05),但明显低于同一时间对照组(P<0.05)。化疗4周期内,观察组发生恶心呕吐严重程度明显较对照组更轻,中重度率显著低于对照组(P<0.05); 两组肝功能损害、腹胀/便秘、皮疹、呃逆、眩晕/嗜睡等非化疗药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论:隔物灸联合阿瑞匹坦及昂丹司琼能有效减轻晚期肺癌患者在顺铂化疗方案中出现的恶心呕吐症状,药物安全性良好且不易于产生耐药性,对改善其预后生存质量有利。
Abstract:
Objective:To explore the clinical effects of substance-partitioned moxibustion combined with aprepitant and ondansetron in preventing gastrointestinal toxicity of cisplatin chemotherapy in patients with advanced lung cancer.Methods:Clinical data of 80 patients with advanced lung cancer chemotherapy were retrospectively analyzed.Patients taking aprepitant and ondansetron alone were included in control group(n=46),and those who were combined with substance-partitioned moxibustion on this basis were included in observation group(n=34).TCM symptoms scores(belching and sour regurgitation,diet reduction,lassitude)were compared between the two groups on the 1st cycle(T1),2nd cycle(T2),3rd cycle(T3)and 4th cycle(T4)of chemotherapy.Occurrence of nausea and vomiting and non-chemotherapeutic adverse reactions were analyzed in the two groups during 4 cycles of chemotherapy.Results:At the end of T1,there were no significant differences in TCM symptoms scores between the two groups(P>0.05).At the end of T2,T3 and T4,there were no significant differences in TCM symptoms scores of belching and sour regurgitation,diet reduction and lassitude in observation group compared with those at the end of T1(P>0.05),but were significantly lower than those in control group at the same time(P<0.05).Within 4 cycles of chemotherapy,severity of nausea and vomiting in observation group was obviously lighter than that in control group,and the moderate-to-severe rate was significantly lower than that in control group(P<0.05).There were no significant differences in incidence rates of non-chemotherapeutic adverse reactions of liver function damage,bloating/constipation,rash,hiccup and dizziness/lethargy between the two groups(P>0.05).Conclusion:Substance-partitioned moxibustion combined with aprepitant and ondansetron can effectively alleviate symptoms of nausea and vomiting in cisplatin chemotherapy of patients with advanced lung cancer.And it has good drug safety,and is not easy to produce drug resistance,thus improving the prognosis and quality of life.

参考文献/References:

[1] 芦殿荣,芦殿香,殷玉琨,等.顺铂导致化疗相关恶心呕吐反应的中药防治[J].长春中医药大学学报,2014,30(4):645-647.
[2] Eberhardt WE,Ruysscher D,Weder W,et al.2nd ESMO consensus conference in lung cancer:locally advanced stage Ⅲ non-small-cell lung cancer[J].Ann Oncol,2015,26(8):1573-1588.
[3] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:134-135.
[4] Basch E,Pugh SL,Dueck AC,et al.Feasibility of patient reporting of symptomatic adverse events via the patient-reported outcomes version of the common terminology criteria for adverse events(pro-ctcae)in a chemoradiotherapy cooperative group multicenter clinical trial[J].Int J Radiat Oncol Biol Phys,2017,98(2):409-418.
[5] 罗群带,李丽美,陶莉莉,等.健脾和胃降逆止呕中药内服加穴位贴敷治疗妊娠恶阻脾胃虚弱证的临床研究[J].广州中医药大学学报,2015,32(4):683-686.
[6] 张 兴,范一宏.电针对化疗所致恶心呕吐的效应及其作用机制[J].中国针灸,2014,34(11):1061-1064.
[7] 张 静,康红刚,王丽萍,等.早期肠内营养对中晚期肺癌合并肺炎患者炎症因子的影响[J].陕西医学杂志,2016,45(10):1318-1320.
[8] 林友燕,方爱军,方 晓.穴位包埋防治顺铂多日方案化疗相关恶心呕吐的临床研究[J].护士进修杂志,2019,34(11):1019-1020.
[9] 宫临征,蔡焦生,赵丽丽,等.补阳还五汤辅助吉西他滨与顺铂化疗对中晚期非小细胞肺癌患者生存质量的影响[J].中医学报,2019,34(4):813-817.
[10] 张孝钦,喻 飒,邬盛昌.人参多糖对晚期肺癌化疗疗效及MDSCs、Treg细胞、免疫因子水平的影响[J].中华全科医学,2019,17(8):1308-1311.
[11] 张 敏,董 勤,徐天舒.艾灸抗肿瘤化疗不良反应临床研究评述[J].肿瘤防治研究,2014,41(1):83-86.
[12] 吴 莉,刘琤琤.多种中医传统灸法联合护理干预减轻鼻咽癌放化疗所致恶心呕吐的疗效观察[J].中医药导报,2019,25(5):113-115.
[13] 濮忠建,马小平,王亚军,等.不同针灸方法治疗化疗所致恶心呕吐临床研究[J].中国中医药信息杂志,2017,24(3):34-37.
[14] Marx W,Ried K,Mccarthy AL,et al.Ginger-mechanism of action in chemotherapy-induced nausea and vomiting:a review[J].Crit Rev Food Sci Nutr,2017,57(1):141-146.
[15] 杨 蕴,张士强,李 芸, 等.针灸治疗化疗后迟发性呕吐及对P物质含量的影响[J].实用中西医结合临床,2019,19(8):50-52.
[16] 刘 炜,徐晓红.艾灸辅助治疗重度妊娠呕吐的效果观察[J].基层医学论坛,2019,23(8):1136-1137.
[17] 张雪萍,邓慧芬,沈秋霞, 等.雷火灸联合帕洛诺司琼治疗对铂类药物化疗患者恶心呕吐反应的应用研究[J].齐齐哈尔医学院学报,2019,40(11):1359-1360.
[18] 赵舒蒙,宋思敏,王 东, 等.古医籍中针灸治疗恶心呕吐腧穴配伍规律的复杂网络分析[J].时珍国医国药,2019,30(7):1764-1767.
[19] 郭亚茹,何诗雯,童 敏, 等.艾灸治疗顺铂化疗所致迟发性呕吐临床研究及经穴分析[J].护理研究,2017,31(24):3023-3027.
[20] 张惠玲.艾灸穴位治疗胃癌患者化疗后恶心、呕吐的临床研究[J].中国社区医师,2018,34(6):104-105.
[21] 范胜军,刘林生,汪松亮.针灸治疗与阿扎司琼在手术患者恶心呕吐治疗中的比较[J].中医临床研究,2018,10(2):122-124.
[22] 龚建强,韩 琦,李洪海,等.针灸治疗呕吐的用穴规律分析[J].针灸临床杂志,2016,32(10):70-73.
[23] 付海东.荆芥防风散配合电针、隔药灸治疗颞下颌关节功能紊乱综合征疗效观察[J].陕西中医,2016,37(4):454-455.
[24] 张国山,刘 密,邱冉冉,等.艾灸与针刺调节功能性消化不良大鼠胃肠动力障碍的对比研究[J].时珍国医国药,2016,27(11):2796-2798.

备注/Memo

备注/Memo:
*广东省科技计划科研项目(2015ZC0428)
更新日期/Last Update: 2020-08-10